Does chemotherapy have a role before hormone-resistant disease develops? (Q37446064)

20 August 2017

1 reference

title

Does chemotherapy have a role before hormone-resistant disease develops? (English)

1 reference

20 August 2017

1 reference

2

Celestia S Higano

1 reference

20 August 2017

James P Dean

1

1 reference

20 August 2017

publication date

1 May 2009

1 reference

20 August 2017

published in

Current urology reports

1 reference

20 August 2017

volume

10

1 reference

20 August 2017

issue

3

1 reference

20 August 2017

page(s)

226-235

1 reference

Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer

20 August 2017

cites work

1 reference

12 December 2020

Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer

1 reference

12 December 2020

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

1 reference

12 December 2020

Combined hormone-chemotherapy for metastatic prostatic carcinoma. Eleven-year follow-up

1 reference

12 December 2020

Randomized Comparison of Goserelin Acetate versus Mitomycin C plus Goserelin Acetate in Previously Untreated Prostate Cancer Patients with Bone Metastases

1 reference

12 December 2020

Prospective and randomized comparison of combined androgen blockade versus combination with oral UFT as an initial treatment for prostate cancer

1 reference

12 December 2020

Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer

1 reference

12 December 2020

Pilot trial of adjuvant paclitaxel plus estramustine in resected high-risk prostate cancer

1 reference

12 December 2020

Chemohormonal therapy as primary treatment for metastatic prostate cancer: a randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist

1 reference

12 December 2020

Neoadjuvant chemohormonal therapy in poor-prognosis localized prostate cancer

1 reference

12 December 2020

Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer

1 reference

12 December 2020

Mitomycin C for metastatic prostate cancer: final analysis of a randomized trial

1 reference

12 December 2020

Long-term control or possible cure? Treatment of stage D2 prostate cancer under chemotherapy using cisplatin and estramustine phosphate followed by maximal androgen blockade

1 reference

12 December 2020

Secondary hormonal therapy for prostate cancer: what lies on the horizon?

1 reference

12 December 2020

Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study

1 reference

12 December 2020

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

1 reference

12 December 2020

Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer

1 reference

12 December 2020

Activity of docetaxel with or without estramustine phosphate versus mitoxantrone in androgen dependent and independent human prostate cancer xenografts

1 reference

12 December 2020

Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer

1 reference

12 December 2020

Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer.

1 reference

12 December 2020

Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer

1 reference

12 December 2020

Neoadjuvant docetaxel treatment for locally advanced prostate cancer: a clinicopathologic study

1 reference

12 December 2020

Adjuvant mitozantrone chemotherapy in advanced prostate cancer

1 reference

12 December 2020

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

1 reference

12 December 2020

Combined versus sequential chemo-endocrine therapy in advanced prostate cancer: final results of a randomized Southwest Oncology Group study

1 reference

12 December 2020

Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer

1 reference

12 December 2020

Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162).

1 reference

12 December 2020

Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer

1 reference

12 December 2020

Feasibility of radical prostatectomy after neoadjuvant chemohormonal therapy for patients with high risk or locally advanced prostate cancer: results of a phase I/II study

1 reference

12 December 2020

Results of another trial of chemotherapy with and without hormones in patients with newly diagnosed metastatic prostate cancer

1 reference

12 December 2020

Long-term follow-up of a neoadjuvant chemohormonal taxane-based phase II trial before radical prostatectomy in patients with non-metastatic high-risk prostate cancer

1 reference

12 December 2020

Molecular alterations in prostate carcinomas that associate with in vivo exposure to chemotherapy: identification of a cytoprotective mechanism involving growth differentiation factor 15.

1 reference

12 December 2020

Phase I study of weekly mitoxantrone and docetaxel before prostatectomy in patients with high-risk localized prostate cancer

1 reference

12 December 2020

Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locally advanced prostate cancer.

1 reference

12 December 2020

Combined hormono/chemotherapy as primary treatment for metastatic prostate cancer: a randomized, multicenter study of orchiectomy alone versus orchiectomy plus estramustine phosphate. The Dutch Estracyt Study Group

1 reference

12 December 2020

Timing is everything: preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancer

1 reference

12 December 2020

The combination of preoperative prostate specific antigen and postoperative pathological findings to predict prostate specific antigen outcome in clinically localized prostate cancer

1 reference

12 December 2020

Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone

1 reference

12 December 2020

Docetaxel, estramustine, and 15-month androgen deprivation for men with prostate-specific antigen progression after definitive local therapy for prostate cancer

1 reference

12 December 2020

Effect of docetaxel in patients with hormone-dependent prostate-specific antigen progression after local therapy for prostate cancer

1 reference

12 December 2020

Randomization reveals unexpected acute leukemias in Southwest Oncology Group prostate cancer trial

1 reference

12 December 2020

Orchiectomy and orchiectomy plus mitomycin C for metastatic prostate cancer in patients with poor prognosis: the final results of a European Organization for Research in Cancer Therapy Genitourinary Group Trial

1 reference

12 December 2020

Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: feasibility and preliminary results

1 reference

12 December 2020

A comparison of diethylstilbestrol or orchiectomy with buserelin and with methotrexate plus diethylstilbestrol or orchiectomy in newly diagnosed patients with clinical stage D2 cancer of the prostate

1 reference

12 December 2020

10.1007/S11934-009-0038-3

Identifiers

DOI

1 reference

20 August 2017

1 reference